INAB

NASDAQ 已收盘

IN8bio

0.76 USD
▼-0.01-1.86%
盘后 0.75 -0.77%
2026-11-20
市值
$8.19M
市盈率
—
EPS
-1.18
股息率
—
52 周区间
0.72 – 2.73
成交量
37.18K
Beta
0.24
目标价
7.00
52W 低 0.7252W 高 2.73
价格走势

公司简介

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinic...